.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
McKinsey
Teva
Cantor Fitzgerald
Fish and Richardson
Cipla
Moodys
Accenture
QuintilesIMS
Queensland Health

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,497,284

« Back to Dashboard

Which drugs does patent 8,497,284 protect, and when does it expire?


Patent 8,497,284 protects CABOMETYX and is included in one NDA.

This patent has fifty-two patent family members in sixteen countries.

Summary for Patent: 8,497,284

Title:C-met modulators and method of use
Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Inventor(s): Bannen; Lynne Canne (Lucerne, CA), Chan; Diva Sze-Ming (Oakland, CA), Chen; Jeff (San Francisco, CA), Dalrymple; Lisa Esther (Seattle, WA), Forsyth; Timothy Patrick (Hayward, CA), Huynh; Tai Phat (Oakland, CA), Jammalamadaka; Vasu (Pleasanton, CA), Khoury; Richard George (San Mateo, CA), Leahy; James William (San Leandro, CA), Mac; Morrison B. (San Francisco, CA), Mann; Grace (San Mateo, CA), Mann; Larry W. (Richland, MI), Nuss; John M. (Danville, CA), Parks; Jason Jevious (Sacramento, CA), Takeuchi; Craig Stacy (Burlingame, CA), Wang; Yong (Foster City, CA), Xu; Wei (Danville, CA)
Assignee: Exelixis, Inc. (South San Francisco, CA)
Application Number:13/249,815
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-001Apr 25, 2016RXYesNo► Subscribe► Subscribe TREATMENT OF RENAL CELL CARCINOMA
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-002Apr 25, 2016RXYesNo► Subscribe► Subscribe TREATMENT OF RENAL CELL CARCINOMA
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-003Apr 25, 2016RXYesYes► Subscribe► Subscribe TREATMENT OF RENAL CELL CARCINOMA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,497,284

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,014,155,378► Subscribe
8,178,532c-Met modulators and method of use► Subscribe
8,476,298c-Met modulators and method of use► Subscribe
9,174,947c-Met modulators and methods of use► Subscribe
8,067,436c-Met modulators and methods of use► Subscribe
7,579,473c-Met modulators and methods of use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,497,284

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria517091► Subscribe
Austria520403► Subscribe
Austria532782► Subscribe
Australia2004275842► Subscribe
Australia2010204459► Subscribe
Australia2010204461► Subscribe
Australia2013204031► Subscribe
Australia2017200555► Subscribe
Canada2537812► Subscribe
Canada2744997► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Mallinckrodt
Citi
Farmers Insurance
QuintilesIMS
Express Scripts
US Department of Justice
Julphar
Deloitte
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot